As the winner of the American Heart Association’s Annual Health Tech Competition, can now access resources and opportunities through the Center for Health Technology & Innovation Innovators’ Network to advance novel heart diagnostics that provide early assessment and appropriate risk stratification of patients presenting with chest pain.


During the Heart Association’s recent Scientific Sessions 2023 in Philadelphia, Carlsbad, California-based RCE Technologies took center stage presenting two prototypes that provide remote measuring and monitoring to aid in the diagnosis and treatment of myocardial heart injury.

The competition looks for innovations that have the potential to transform the landscape of heart and brain health. Submissions must involve, engage or support patient treatment and solve a pervasive problem in antithrombotic, coronary artery disease/acute coronary syndrome, cardiometabolic, electrophysiology, heart failure, hypertension, imaging, lipids, resuscitation, stroke, surgery or vascular medicine.

RCE produces noninvasive instant measurement of cardiac proteins in blood – a noninvasive transdermal technique – to improve patient outcomes and reduce hospital length of stay and healthcare costs, according to the association’s announcement last week.

The company will further develop its noninvasive, instant measurement of cardiac proteins and virtual heart failure management – including wearable sensors for ready detection and presymptomatic detection – in collaboration with the consortium, which aims to reduce the cost of developing health technology independently, the association said. 

Judges reviewed other technologies for the treatment and prevention of cardiovascular diseases and stroke developed by five finalists, which also included Ainthoven, based in Melbourne, Florida; CardieX, of Naperville, Illinois; Cardiosense in Chicago; and PyrAmes, based in Cupertino, California. 

They selected PyrAmes as the best business pitch, and Cardiosense as the best science pitch, based on their validity, scientific rigor and potential to improve patient outcomes, the association said.


In July, RCE was inducted into the Cedars-Sinai Accelerator program, a three-month program that provides companies with $100,000 in funding and mentorship.

“The point-of-care trending of the composite of acute cardiac injury biomarkers can empower emergency medicine physicians and cardiologists in the early assessment and appropriate risk stratification of patients presenting with chest pain,” according to RCE. 

Artificial intelligence and machine learning are being used to improve the detection of heart disease. 

In 2022, the NHS began using AI to detect heart disease in 20 seconds while patients were in an MRI scanner. A British Heart Foundation-funded study published in the Journal of Cardiovascular Magnetic Resonance concluded the ML had superior precision to three clinicians. 

The previous year, the Mayo Clinic published a study in Nature where an AI-enabled electrocardiogram helped identify patients who would have “slipped through the cracks.” 

“The takeaway is that we are likely to see more AI use in the practice of medicine as time goes on,” said Dr. Peter Noseworthy, the Mayo Clinic cardiac electrophysiologist who was the senior author of the 2021 study.


Atandra Burman, founder and CEO of RCE Technologies, said in the statement the company is focused on empowering healthcare professionals to provide the best patient care in real time.

Andrea Fox is senior editor of Healthcare IT News.

Healthcare IT News is a HIMSS Media publication.

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *